Archer® Solid Tumor assays provide a targeted sequencing approach to detect various driver mutation types in solid tumors. This approach combines FusionPlex®, VariantPlex® and Reveal-ctDNA™ kits to characterize gene fusions, CNVs and other variants from a single, low-input FFPE sample and liquid biopsy.
Need to modify your panel?
Add any of our wet lab-validated designs to this panel with Archer Assay Designer to build an assay that fits your exact requirements.
Tell us a little about yourself and your needs, and a member of our gregarious sales team will reach out to you regarding the assays you selected in Step 2.
* Indicates required fields.
Catalog kits that are on the shelf and ready for delivery
Pre-bundled kits that complement each other to deliver superior mutation profiling from solid tumors and liquid biopsies
Predesigned panels that can be delivered in 3-4 weeks
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Mutation profiling of low-input clincal type samples such as FFPE using conventional detection methods (e.g., karyotyping, IHC, RT-PCR and FISH) is impractical, because 1) conventional methods lack the multiplexing capability to detect mutations across multiple gene targets and 2) they cannot detect different mutation types in a single workflow. All Archer kits employ AMP™ target enrichment chemistry to detect both known and unknown mutations across relevant target genes. Combine Archer NGS kits into a comprehensive, targeted sequencing workflow to detect fusions, CNVs, SNVs and indels in genes associated with an array of carcinomas.
Detecting somatic mutations in RNA, DNA and ctDNA provides internal cross verification. Not only can fusions be verified by a detected expression imbalance, but CNVs and expression profiles can verify or classify oncogenic mechanisms. Also, SNVs found in both RNA and DNA can confirm the presence of the mutation, expression and potential allelic imbalance. Concordance studies have never been so powerful and easy to perform.
Expression imbalance for fusion confirmation
Functional gene fusions result in overexpression of one portion of the gene and lack of expression in the portion that has been translocated away, which results in an imbalance of expression levels within the gene of interest. AMP chemistry uses molecular barcodes that enable unique molecule counting across a region to assess expression level differences. Archer FusionPlex kits calculate expression imbalance as a confirmatory method for detected gene fusions.
Expression profiling for CNV confirmation
In AMP chemistry, molecular barcodes are ligated to unique input molecules prior to amplification. Counting and analyzing unique molecules allows for robust CNV detection in DNA and expression profiling in RNA. Comparing the two can verify results or classify oncogenic mechanism of the tumor.
SNV verification using RNA & DNA
Overlapping hotspot coverage in FusionPlex and VariantPlex kits enables SNV and indel cross-verification. Differences in allelic fraction (AF) detection can be attributed to RNA expression levels. In this case, the EGFR variant is driving the allelic imbalance.
2477 55th Street, Suite 202
Boulder, CO 80301